301371 Harbin Fuerjia Technology
- 36.83
- -0.54-1.45%
Harbin Fuerjia Technology News
Fosun Pharma (301371): Income growth accelerates, reorganization progresses on three categories of collagen medical devices.
In the third quarter of 2024, the company achieved revenue of 0.527 billion yuan, an 11.88% year-on-year increase, and achieved a net income attributable to the parent company of 0.173 billion yuan, a 5.16% year-on-year decline. In the third quarter, the company maintained its two.
Fulijia (301371): Q3 revenue 0.527 billion, YOY +11.88%, steady growth.
Event: The company released its third quarter report for 2024. The revenue for Q1-Q3 of 2024 was 1.466 billion, with a year-on-year increase of 9.47%; the net profit attributable to the parent company was 0.514 billion yuan, a year-on-year decrease of 4.2%. In Q3 of 2024, the company achieved revenue of 5.
Fusion Tech (301371): Steady growth in Q3 revenue. Freeze-dried fibers completed clinical filing, taking the first step in medical aesthetics.
Event: For the third quarter of 2024, Fuli Jia disclosed its performance: Q1-3 2024: revenue of 1.466 billion yuan, +9%, net income attributable to shareholders of 0.514 billion yuan, -4%. Q3 2024: revenue of 0.527 billion yuan, +12%, net income attributable to shareholders
Fujia (301371): Performance meets expectations, bullish on strong research and development driving rapid introduction of new products.
Investment Highlights Q3 Revenue growth accelerated on a month-on-month basis, performance met expectations: (1) 24Q1-Q3: achieved revenue of 1.466 billion, +9.47% year-on-year, gross margin of 81.65%, slightly decreased by 0.73 percentage points year-on-year, selling expenses.
Express News | Fu Er Jia: The november 11 shopping festival-related event layout has been completed.
Fosun Pharma (301371): Steady revenue growth, promising future in the pipeline under research.
Event: The company released the third quarter report of 2024: In 2024Q1-Q3, the company achieved revenue of 1.466 billion yuan, +9.47% year-on-year, achieved a net income attributable to mother of 0.514 billion yuan, -4.20% year-on-year, achieving a non-net income.
Fujia (301371): Increased market investment in Q3 boosts revenue growth marginally.
Fujia released its third quarter report: Q3 revenue of 0.527 billion yuan (yoy +11.88%), net profit attributable to parent company of 0.173 billion yuan (yoy -5.16%). 24Q1-Q3 revenue 1.466 billion yuan (yoy+)
Fujia (301371) 2024 Third Quarter Report Review: Q3 24 revenue +11.9% year-on-year, gradually precipitating brand strength and product strength.
Event overview. Fulcrum released the third quarter report for 2024. In Q1-Q3 of 24, revenue reached 1.466 billion yuan, a year-on-year increase of +9.47%, achieving a net income attributable to the parent of 0.514 billion yuan, a year-on-year decrease of -4.20%, achieving deductions
Shiljia: Report for the third quarter of 2024
Fusen Pharmaceutical (301371.SZ) released its performance for the first three quarters, with a net income of 0.514 billion yuan, a decrease of 4.20%.
Fujia (301371.SZ) released its third-quarter report for 2024, with revenue for the first three quarters of the company at 14...
Fuljia (301371.SZ): Online revenue accounted for 50.26% in the first half of the year, while offline revenue accounted for 49.74%.
On September 29, Gelonghui reported that Fulcrum (301371.SZ) conducted a survey for specific parties on September 27, 2024, regarding 'What is the current proportion of online and offline revenue for the company?' The company stated that in the first half of this year, our online revenue accounted for 50.26%, while offline revenue accounted for 49.74%.
Fosun Pharma (301371.SZ): Currently, in the product design input and pilot stages, the recombination of Class III medical instruments, type III human-derived collagen filler.
Gelonghui September 29th丨 Furka (301371.SZ) accepted a specific object survey on September 27, 2024, regarding "How is the progress of the company's Class III medical instruments filling products?", the company stated that the Class III medical instrument filling product restructuring Type III recombinant human collagen filler is in the product design input, small-scale trial stage, and the R&D progress is as expected.
Fujia (301371.SZ): In August, more than 10 new products were launched, and the sales of new products met expectations, with some new products exceeding expectations.
On September 29, Gelonghui reported that Fulljia (301371.SZ) accepted a specific survey on September 27, 2024, regarding "What new products did the company launch in August and how is the sales situation?" The company stated that in August of this year, the company successfully transformed research and development achievements, launching more than 10 new products, including the heavyweight new product Grape Seed Trace Brightening and Tender Emulsion Mask utilizing supramolecular technology, White Pool Flower Seed Brightening and Nourishing Skin Emulsion Mask, and Luminous Essence Water, as well as self-developed products like Lactobionic Acid Oil-Control Refining Mask. Currently, the sales of new products are meeting expectations, with some exceeding expectations. It is hoped that these new products will bring benefits to the company in the second half of the year.
Fujia (301371.SZ): Shanghai R&D Center is the company's research headquarters in the cosmetic field.
On September 29, Gelonhui reported that Euclidia (301371.SZ) accepted specific inquiries on September 27, 2024, regarding "Please introduce the situation of the company's Shanghai R&D center". The company stated that the Shanghai R&D center is the company's research and development base in the cosmetic industry, aiming to strengthen independent research capabilities and support the company's long-term sustainable development. The establishment of the Shanghai R&D center signifies that Euclidia has taken a solid step on the path of scientific research and innovation, which will collaborate with the Harbin R&D center, synchronize north and south, connect with cutting-edge technology in the industry, continuously enhance independent research and innovation capabilities, accelerate raw material exploration, new technology development, and product innovation.
Fosun Pharma (301371.SZ): The future sales of Class III medical instruments will mainly be aimed at qualified plastic surgery institutions, hospitals, etc.
On September 29, Julaon Hui reported that Fora (301371.SZ) accepted a specific object survey on September 27, 2024, asking "What are the future sales channels for Class III medical instruments, and will a dedicated sales team be established?" The company stated that the future sales of Class III medical instruments will mainly be targeted towards qualified plastic surgery institutions, hospitals, etc., and the company will consider establishing a sales team for Class III medical instruments in the future.
Express News | Forscan: Completion of clinical trial filing for restructured collagen protein products.
Fu Er Jia (301371): H1 2024 achieves revenue YoY +8.17%, with continuous growth in online direct sales.
Event: The company released its half-year report for 24. 24H1 revenue was 0.94 billion, yoy +8.17%; net profit attributable to the parent company was 0.34 billion yuan, yoy -3.71%, non-GAAP net profit attributable to the parent company was 0.324 billion. 24Q2 Company actual
Fu'erjia (301371.SZ): The registration inspection of Type III humanized collagen freeze-dried fiber for recombination has been completed, and it is expected to take about one year for the clinical stage.
On September 9, Gelonhui | Fuljia (301371.SZ) accepted a specific investigation on September 9, 2024, regarding the progress of the company's Class III medical instruments. The company stated that the progress of our Class III medical instruments is basically in line with expectations. The fastest progress is our reconstituted Type III human-sourced collagen freeze-dried fibers, which have now completed registration testing. The next step is the clinical stage, with an expected duration of about one year. If the progress proceeds as expected, this product will be our first Class III medical instrument product launched.
Currently, the company has 4 types of medical instruments products in the category II.
On September 9, Gelunhui reported that Fuljia (301371.SZ) conducted a specific object survey on September 9, 2024, regarding "How many types of Class II medical instruments the company currently sells, and whether there are any product reserves in the future?" The company stated that there are currently 4 types of Class II medical instruments, including: Medical Hyaluronic Acid Sodium Repair Patch (White Film), Medical Hyaluronic Acid Sodium Repair Patch (Black Film), Medical Hyaluronic Acid Sodium Repair Liquid, Medical Recombinant Type III Human Collagen Patch. The company is also developing two more types of Class II medical instruments, namely Medical Seaweed Glucose Repair Patch and Medical Polyglutamic Acid Sodium Repair Patch.
Furunvita (301371.SZ): The online channel revenue in the first half of the year was 0.472 billion yuan, accounting for 50.26%.
On September 9th, 2024, Furejia (301371.SZ) received a specific object survey on whether the future sales of the company will be more inclined towards online or offline. The company stated that in recent years, online revenue has continued to grow, and there is still a relatively large online space. The company adopts a deep collaboration of online and offline sales channels, creating a diversified terminal consumer scene with direct sales, distribution, and agent distribution covering all channels. In the first half of this year, online channel revenue was 0.472 billion yuan, accounting for 50.26%, and offline channel revenue was 0.467 billion yuan, accounting for 49.74%. In the future...
Analysis
Price Target
No Data
No Data